Skip to main content
. 2021 Mar 17;23(7):1033–1041. doi: 10.1093/europace/euab029

Table 4.

Serious adverse events

Adverse event, events (subjects) Cryoballoon CA (n = 107)
AAD (n = 111)
All Procedure related System related All Drug related Procedure related (cross over)
Total 42 (26) 11 (9) 2 (1) 56 (37) 4 (4) 1 (1)
Acute coronary syndrome 0 0 0 1 (1) 0 0
Acute kidney injury 0 0 0 1 (1) 0 0
Adverse drug reaction 0 0 0 3 (3) 2 (2) 0
Arteriospasm coronary 1 (1) 1 (1) 0 0 0 0
Atrial arrhythmia recurrence 15 (11) 1 (1) 0 34 (28) 2 (2) 0
AVNRT 1 (1) 0 0 0 0 0
Bronchitis 1 (1) 0 0 0 0 0
Chest pain 1 (1) 0 0 0 0 0
Gastrointestinal pain 1 (1) 0 0 0 0 0
Impaired gastric emptying 1 (1) 1 (1) 0 1 (1) 0 0
Impaired healing 0 0 0 1 (1) 0 0
Lung disorder/infection 4 (1) 1 (1) 0 0 0 0
Non-sustained ventricular tachycardia 0 0 0 1 (1) 0 0
Oedema peripheral 0 0 0 1 (1) 0 0
Orthostatic hypotension 0 0 0 1 (1) 0 0
Palpitations 0 0 0 1 (1) 0 0
Pericardial disordera 3 (3) 3 (3) 1 (1) 0 0 0
Phrenic nerve paralysis 0 0 0 0 1 (1)b 0 1 (1)
Pneumonia 1 (1) 0 0 0 0 0
Procedural failurec 1 (1) 1 (1) 0 0 0 0
Pyrexia 1 (1) 1.(1) 0 0 0 0
Syncope 0 0 0 1 (1) 0 0
Transient ischaemic attack 1 (1) 1 (1) 1 (1) 0 0 0
Vascular access site haemorrhage 1 (1) 1 (1) 0 0 0 0
Other 9 (9) 0 0 9 (7) 0 0

Atrial arrhythmia recurrence was only classified as a serious adverse event if it resulted in hospitalization.

a

None of these events resulted in cardiac tamponade.

b

Transient phrenic nerve palsy was experienced by one subject randomized to AAD who underwent CA.

c

Failure of the transseptal puncture was observed in one subject randomized to cryoballoon; a second procedure was successful.

AAD, antiarrhythmic drug; AVNRT, atrioventricular nodal reentry tachycardia; CA, catheter ablation.